Skip to main content
Fig. 3 | Journal of Neuroinflammation

Fig. 3

From: A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington’s disease

Fig. 3

MCC950 markedly reduces disease progression in a transgenic mouse model (R6/2) of HD. Mice were treated daily with MCC950 (10 mg/kg of body weight; oral administration) or water for 5 weeks from the age of 7 weeks. Rotarod performance (A), clasping (B), and body weight (C) (n = 16–20 for each condition) were assessed. Data are presented as the mean ± SEM. *P < 0.05, WT vs. R6/2 mice; #P < 0.05 vs. water-treated R6/2 mice. D Survival assessment (n = 16–20 for each condition; P < 0.05, Kaplan–Meier survival analysis)

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094